RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Haemonetics Stock

Haemonetics EBIT 2024

Haemonetics EBIT

213.23 M USD

Ticker

HAE

ISIN

US4050241003

WKN

881782

In 2024, Haemonetics's EBIT was 213.23 M USD, a 26.77% increase from the 168.2 M USD EBIT recorded in the previous year.

The Haemonetics EBIT history

YEAREBIT (undefined USD)
2028e601.96
2027e442.12
2026e385.77
2025e332.64
2024213.23
2023168.2
2022100.6
202173.6
2020173.9
2019118.3
2018100
201739.2
201643.8
2015103
201448.1
201360.6
2012105
2011116.9
201096.6
200985.6
200870.3
200766.1
200671.9
200559.4

Haemonetics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Haemonetics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Haemonetics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Haemonetics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Haemonetics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Haemonetics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Haemonetics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Haemonetics’s growth potential.

Haemonetics Revenue, EBIT and net profit per share

DateHaemonetics RevenueHaemonetics EBITHaemonetics Net Income
2028e1.97 B undefined601.96 M undefined439.54 M undefined
2027e1.62 B undefined442.12 M undefined323.05 M undefined
2026e1.48 B undefined385.77 M undefined272.31 M undefined
2025e1.41 B undefined332.64 M undefined235.99 M undefined
20241.31 B undefined213.23 M undefined117.56 M undefined
20231.17 B undefined168.2 M undefined115.4 M undefined
2022993.2 M undefined100.6 M undefined43.4 M undefined
2021870.5 M undefined73.6 M undefined79.5 M undefined
2020988.5 M undefined173.9 M undefined76.5 M undefined
2019967.6 M undefined118.3 M undefined55 M undefined
2018903.9 M undefined100 M undefined45.6 M undefined
2017886.1 M undefined39.2 M undefined-26.3 M undefined
2016908.8 M undefined43.8 M undefined-55.6 M undefined
2015910.4 M undefined103 M undefined16.9 M undefined
2014938.5 M undefined48.1 M undefined35.1 M undefined
2013892 M undefined60.6 M undefined38.8 M undefined
2012727.8 M undefined105 M undefined66.9 M undefined
2011676.7 M undefined116.9 M undefined80 M undefined
2010645.4 M undefined96.6 M undefined58.4 M undefined
2009597.9 M undefined85.6 M undefined59.3 M undefined
2008516.4 M undefined70.3 M undefined52 M undefined
2007449.6 M undefined66.1 M undefined49.1 M undefined
2006419.7 M undefined71.9 M undefined68.4 M undefined
2005383.6 M undefined59.4 M undefined39.2 M undefined

Haemonetics stock margins

The Haemonetics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Haemonetics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Haemonetics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Haemonetics's sales revenue. A higher gross margin percentage indicates that the Haemonetics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Haemonetics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Haemonetics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Haemonetics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Haemonetics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Haemonetics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Haemonetics Margin History

Haemonetics Gross marginHaemonetics Profit marginHaemonetics EBIT marginHaemonetics Profit margin
2028e54.13 %30.6 %22.35 %
2027e54.13 %27.29 %19.94 %
2026e54.13 %26.15 %18.46 %
2025e54.13 %23.52 %16.69 %
202454.13 %16.29 %8.98 %
202353.3 %14.39 %9.87 %
202252.92 %10.13 %4.37 %
202146.81 %8.45 %9.13 %
202049.35 %17.59 %7.74 %
201945.34 %12.23 %5.68 %
201845.57 %11.06 %5.04 %
201742.72 %4.42 %-2.97 %
201644.66 %4.82 %-6.12 %
201547.72 %11.31 %1.86 %
201449.91 %5.13 %3.74 %
201347.99 %6.79 %4.35 %
201250.73 %14.43 %9.19 %
201152.49 %17.28 %11.82 %
201052.29 %14.97 %9.05 %
200951.55 %14.32 %9.92 %
200849.9 %13.61 %10.07 %
200750.51 %14.7 %10.92 %
200652.39 %17.13 %16.3 %
200551.49 %15.48 %10.22 %

Haemonetics Aktienanalyse

What does Haemonetics do?

Haemonetics Corp is a leading provider of blood processing and transfusion products. The company was founded in 1971 by Dr. Jack Latham to create a better solution for the storage and transfer of blood products. Since then, the company has become a major provider of products and services for the blood transfusion industry. Haemonetics' business model is focused on the development, manufacturing, and marketing of products and devices for blood transfusion. The company offers a wide range of products and services, including blood processing systems, blood collection and maintenance devices, software solutions, blood components, and related accessories. In recent years, Haemonetics has dedicated itself to diversifying its offerings. While still focusing on the blood transfusion industry, the company has also expanded into other areas, such as the treatment of patients with blood disorders and the development of devices for cell therapy. Haemonetics is divided into various business segments, including Blood Management Solutions, Diagnostic Solutions, and Haemonetics Software Solutions. The Blood Management Solutions segment includes a range of products, including blood collection and storage devices, centrifuges, and hematocrit systems. Diagnostic Solutions provides diagnostic tests for blood disorders, including tests for coagulation disorders and thrombophilia. Haemonetics Software Solutions offers software solutions for the blood transfusion industry, including systems for automated processing and storage of blood products, as well as systems for automatic inventory management. Haemonetics' products also include devices for freezing blood products and for processing blood components. These devices help ensure that blood products are stored at optimal temperatures and conditions to ensure their effectiveness and usability for the patient. Another important area of Haemonetics' business is the development of devices for cell therapy. The company works closely with research institutes and biotech companies to develop innovative technologies for cell therapy. This includes the development of devices for the isolation and purification of stem cells that can be used for the treatment of cancer and other diseases. Haemonetics Corp has made a name for itself in the blood transfusion industry and continues to focus on innovation and diversification to fully utilize the potential of the company and its products. With a wide range of products and services, a strong commitment to research and development, and an unwavering focus on the needs of patients and healthcare providers, Haemonetics is well positioned to continue growing and expanding in the future. Haemonetics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing Haemonetics's EBIT

Haemonetics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Haemonetics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Haemonetics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Haemonetics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Haemonetics stock

How much did Haemonetics achieve in EBIT for the current year?

In the current year, Haemonetics has achieved an EBIT of 213.23 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Haemonetics.

How has the EBIT of Haemonetics developed in recent years?

The EBIT of Haemonetics has increased by 26.774% increased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company Haemonetics?

The EBIT of Haemonetics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does Haemonetics pay?

Over the past 12 months, Haemonetics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Haemonetics is expected to pay a dividend of 0 USD.

What is the dividend yield of Haemonetics?

The current dividend yield of Haemonetics is .

When does Haemonetics pay dividends?

Haemonetics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Haemonetics?

Haemonetics paid dividends every year for the past 0 years.

What is the dividend of Haemonetics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Haemonetics located?

Haemonetics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Haemonetics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Haemonetics from 8/11/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/11/2024.

When did Haemonetics pay the last dividend?

The last dividend was paid out on 8/11/2024.

What was the dividend of Haemonetics in the year 2023?

In the year 2023, Haemonetics distributed 0 USD as dividends.

In which currency does Haemonetics pay out the dividend?

The dividends of Haemonetics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Haemonetics

Our stock analysis for Haemonetics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Haemonetics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.